These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 37493197)

  • 1. ALSUntangled #71: Nuedexta.
    Sun Y; Benatar M; Mascías Cadavid J; Ennist D; Wicks P; Staats K; Beauchamp M; Jhooty S; Pattee G; Brown A; Bertorini T; Barkhaus P; Bromberg M; Carter G; Bedlack R; Li X
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):218-222. PubMed ID: 37493197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
    Smith R; Pioro E; Myers K; Sirdofsky M; Goslin K; Meekins G; Yu H; Wymer J; Cudkowicz M; Macklin EA; Schoenfeld D; Pattee G
    Neurotherapeutics; 2017 Jul; 14(3):762-772. PubMed ID: 28070747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.
    Yang LP; Deeks ED
    Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dextromethorphan/quinidine sulfate for pseudobulbar affect.
    Rosen H
    Drugs Today (Barc); 2008 Sep; 44(9):661-8. PubMed ID: 19137121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.
    Fralick M; Sacks CA; Kesselheim AS
    JAMA Intern Med; 2019 Feb; 179(2):224-230. PubMed ID: 30615021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.
    Pioro EP
    Neurol Ther; 2014 Jun; 3(1):15-28. PubMed ID: 26000221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
    Olney N; Rosen H
    IDrugs; 2010 Apr; 13(4):254-65. PubMed ID: 20373255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
    Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
    BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
    Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
    Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect.
    Med Lett Drugs Ther; 2011 Jun; 53(1366):46-7. PubMed ID: 21659969
    [No Abstract]   [Full Text] [Related]  

  • 12. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis.
    Green JR; Allison KM; Cordella C; Richburg BD; Pattee GL; Berry JD; Macklin EA; Pioro EP; Smith RA
    Br J Clin Pharmacol; 2018 Dec; 84(12):2849-2856. PubMed ID: 30152872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dextromethorphan/quinidine: in pseudobulbar affect.
    Garnock-Jones KP
    CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use.
    Taylor CP; Traynelis SF; Siffert J; Pope LE; Matsumoto RR
    Pharmacol Ther; 2016 Aug; 164():170-82. PubMed ID: 27139517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pseudobulbar affect (PBA) in a patient with a history of traumatic brain injury, partial brain resection, and brainstem stroke: a case report.
    Young FG; Nguyen D
    J Med Case Rep; 2020 Dec; 14(1):235. PubMed ID: 33272325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine.
    Garcia-Baran D; Johnson TM; Wagner J; Shen J; Geers M
    Medicine (Baltimore); 2016 Mar; 95(12):e2886. PubMed ID: 27015166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NueDexta: A Treatment for Pseudobulbar Affect.
    Roman MW
    Issues Ment Health Nurs; 2015; 36(12):1019-21. PubMed ID: 26735510
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
    Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
    Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
    Doody RS; D'Amico S; Cutler AJ; Davis CS; Shin P; Ledon F; Yonan C; Siffert J
    CNS Spectr; 2016 Dec; 21(6):450-459. PubMed ID: 26471212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.
    Tabor Gray L; Locatelli E; Vasilopoulos T; Wymer J; Plowman EK
    Ann Clin Transl Neurol; 2023 Aug; 10(8):1296-1304. PubMed ID: 37265174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.